Spark Therapeutics, Inc.

Form 3

January 29, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person *

Mehra Anand

(Last)

(First)

(Middle)

Statement

(Month/Day/Year)

01/29/2015

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

Spark Therapeutics, Inc. [ONCE]

C/O SOFINNOVA

VENTURES, Â 3000 SAND HILL ROAD, 4-250

(Street)

4. Relationship of Reporting

Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

(Check all applicable)

X Director __X__ 10% Owner Officer Other (give title below) (specify below)

6. Individual or Joint/Group

Filing(Check Applicable Line) Form filed by One Reporting

Person

X Form filed by More than One

Reporting Person

MENLO PARK. CAÂ 94025

(City) (State) (Zip)

1. Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned

(Instr. 4)

3. Ownership

Table I - Non-Derivative Securities Beneficially Owned

4. Nature of Indirect Beneficial Ownership

Form: (Instr. 5)

Direct (D) or Indirect (I) (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially

owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security

(Instr. 4)

2. Date Exercisable and **Expiration Date**

(Month/Day/Year)

Exercisable

3. Title and Amount of Securities Underlying **Derivative Security**

or Exercise Price of

5 Ownership Conversion Form of

6. Nature of Indirect Beneficial

Ownership

(Instr. 5)

(Instr. 4)

Expiration Date

Title Amount or Number of Derivative Security

4.

Derivative Security: Direct (D)

1

Edgar Filing: Spark Therapeutics, Inc. - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Stock Option (right to buy)	(1)	08/11/2024	Common Stock	37,203	\$ 3.45	D (2)	Â
Series B Convertible Preferred Stock	(3)(4)	(3)(4)	Common Stock	1,863,354	\$ (3) (4)	I	See footnote (5)

Reporting Owners

Reporting Owner Name / Address		Relationships				
	Director	10% Owner	Officer	Other		
Mehra Anand C/O SOFINNOVA VENTURES 3000 SAND HILL ROAD, 4-250 MENLO PARK, CA 94025	ÂX	ÂX	Â	Â		
Sofinnova Venture Partners VIII, L.I 3000 SAND HILL ROAD, 4-250 MENLO PARK, CA 94025	P. Â	ÂX	Â	Â		
Sofinnova Management VIII, L.L.C. 3000 SAND HILL ROAD, 4-250 MENLO PARK, CA 94025	Â	ÂX	Â	Â		
AKKARAJU SRINIVAS 18 DESBROSSES STREET NEW YORK, NY 10013	Â	ÂX	Â	Â		
HEALY JAMES 3000 SAND HILL ROAD, 4-250 MENLO PARK, CA 94025	Â	ÂX	Â	Â		
POWELL MICHAEL 3000 SAND HILL ROAD, 4-250 MENLO PARK, CA 94025	Â	ÂX	Â	Â		

Signatures

/s/ Nathalie Auber, attorney-in-fact for Anand Mehra				
**Signature of Reporting Person	Date			
/s/ Nathalie Auber, attorney-in-fact for Sofinnova Venture Partners VIII, L.P.				
**Signature of Reporting Person	Date			
/s/ Nathalie Auber, attorney-in-fact for Sofinnova Management VIII, L.L.C.				
**Signature of Reporting Person	Date			
/s/ Nathalie Auber, attorney-in-fact for Srinivas Akkaraju				
**Signature of Reporting Person	Date			

Reporting Owners 2

Edgar Filing: Spark Therapeutics, Inc. - Form 3

01/29/2015

Date

/s/ Nathalie Auber, attorney-in-fact for James I. Healy

**Signature of Reporting Person

/s/ Nathalie Auber, attorney-in-fact for Michael F. Powell 01/29/2015

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations, See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option was granted on August 11, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter.
- (2) The securities are owned directly by Mr. Mehra.
 - Consists of shares of Series B Convertible Preferred Stock issued on May 23, 2014, that are currently convertible into 1,863,354 shares of Common Stock. Shares of Series B Convertible Preferred Stock accrue stock dividends payable in additional shares of Series B Convertible Preferred Stock at a rate of 8% per annum from November 23, 2014. Shares of Series B Convertible Preferred Stock,
- (3) including shares of Series B Convertible Preferred Stock issued as accrued stock dividends, are immediately convertible into shares of Common Stock upon issuance, will be automatically converted into shares of Common Stock immediately upon the closing of the issuer's initial public offering pursuant to a registration statement on Form S-1 under the Securities Act of 1933, as amended, and have no expiration date.
- The aggregate amount of stock dividends that will have accrued through February 4, 2015, the expected closing date of the initial public offering, is 30,222 shares of Common Stock. The above Common Stock share equivalent numbers are rounded down to the nearest whole share number.
 - The securities are owned directly by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII"), the general partner of SVP VIII, and Anand Mehra, a director of the Issuer, James I. Healy, Srinivas Akkaraju, and Michael
- (5) Powell, the managing members of SM VIII, may be deemed to have shared voting and dispositive power over the shares owned by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares owned by SVP VIII except to the extent of any pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3